Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Enliven Therapeutics, Inc. (ELVN)

41.69 -3.78 (-8.31%)
As of 10:46:11 AM EDT. Market Open.
Trade ELVN on Coinbase
Chart Range Bar
Loading chart for ELVN
  • Previous Close 45.47
  • Open 45.38
  • Bid 32.40 x 200
  • Ask 53.12 x 200
  • Day's Range 41.22 - 45.60
  • 52 Week Range 14.78 - 62.32
  • Volume 317,663
  • Avg. Volume 1,108,600
  • Market Cap (intraday) 3.055B
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) --
  • EPS (TTM) -1.67
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 73.67

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

www.enliventherapeutics.com

67

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ELVN
167.66%
S&P 500 (^GSPC)
14.30%

1-Year Return

ELVN
103.05%
S&P 500 (^GSPC)
16.09%

3-Year Return

ELVN
214.18%
S&P 500 (^GSPC)
81.61%

5-Year Return

ELVN
174.80%
S&P 500 (^GSPC)
79.32%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -32.48M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

64.00
73.67 Average
41.69 Current
82.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/2/2026
Analyst Morgan Stanley
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 70

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    3.38B

  • Enterprise Value

    2.48B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.77

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -11.00%

  • Return on Equity (ttm)

    -15.31%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -105.93M

  • Diluted EPS (ttm)

    -1.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    895.16M

  • Total Debt/Equity (mrq)

    0.17%

  • Levered Free Cash Flow (ttm)

    -45.26M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

41.69 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: